326 related articles for article (PubMed ID: 21351211)
1. Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE.
Löfberg R; Louis EV; Reinisch W; Robinson AM; Kron M; Camez A; Pollack PF
Inflamm Bowel Dis; 2012 Jan; 18(1):1-9. PubMed ID: 21351211
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab safety in global clinical trials of patients with Crohn's disease.
Colombel JF; Sandborn WJ; Panaccione R; Robinson AM; Lau W; Li J; Cardoso AT
Inflamm Bowel Dis; 2009 Sep; 15(9):1308-19. PubMed ID: 19434735
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease.
Barreiro-de-Acosta M; Lorenzo A; Domínguez-Muñoz JE
Rev Esp Enferm Dig; 2012 Sep; 104(9):468-72. PubMed ID: 23130854
[TBL] [Abstract][Full Text] [Related]
5. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
6. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.
Louis E; Löfberg R; Reinisch W; Camez A; Yang M; Pollack PF; Chen N; Chao J; Mulani PM
J Crohns Colitis; 2013 Feb; 7(1):34-43. PubMed ID: 22480772
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
Sandborn WJ; Rutgeerts P; Enns R; Hanauer SB; Colombel JF; Panaccione R; D'Haens G; Li J; Rosenfeld MR; Kent JD; Pollack PF
Ann Intern Med; 2007 Jun; 146(12):829-38. PubMed ID: 17470824
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.
Schoepfer AM; Vavricka SR; Binek J; Felley C; Geyer M; Manz M; Rogler G; de Saussure P; Sauter B; Seibold F; Straumann A; Michetti P;
Inflamm Bowel Dis; 2010 Jun; 16(6):933-8. PubMed ID: 20014021
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study.
Zorzi F; Zuzzi S; Onali S; Calabrese E; Condino G; Petruzziello C; Ascolani M; Pallone F; Biancone L
Aliment Pharmacol Ther; 2012 Jun; 35(12):1397-407. PubMed ID: 22519466
[TBL] [Abstract][Full Text] [Related]
12. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.
Watanabe M; Hibi T; Lomax KG; Paulson SK; Chao J; Alam MS; Camez A;
J Crohns Colitis; 2012 Mar; 6(2):160-73. PubMed ID: 22325170
[TBL] [Abstract][Full Text] [Related]
14. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
Absah I; Faubion WA
Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
[TBL] [Abstract][Full Text] [Related]
16. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.
Lichtiger S; Binion DG; Wolf DC; Present DH; Bensimon AG; Wu E; Yu AP; Cardoso AT; Chao J; Mulani PM; Lomax KG; Kent JD
Aliment Pharmacol Ther; 2010 Nov; 32(10):1228-39. PubMed ID: 20955442
[TBL] [Abstract][Full Text] [Related]
17. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial.
Rutgeerts P; Van Assche G; Sandborn WJ; Wolf DC; Geboes K; Colombel JF; Reinisch W; ; Kumar A; Lazar A; Camez A; Lomax KG; Pollack PF; D'Haens G
Gastroenterology; 2012 May; 142(5):1102-1111.e2. PubMed ID: 22326435
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
Sandborn WJ; Hanauer SB; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh DG; Panaccione R; Wolf D; Kent JD; Bittle B; Li J; Pollack PF
Gut; 2007 Sep; 56(9):1232-9. PubMed ID: 17299059
[TBL] [Abstract][Full Text] [Related]
20. Adalimumab for maintenance therapy for one year in Crohn's disease: results of a Latin American single-center observational study.
Kotze PG; Abou-Rejaile VR; Uiema LA; Olandoski M; Sartor MC; Miranda EF; Kotze LM; Saad-Hossne R
Arq Gastroenterol; 2014; 51(1):39-45. PubMed ID: 24760063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
